158 related articles for article (PubMed ID: 38799557)
1. NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens.
Oh J; Kirsh C; Hsin JP; Radecki KC; Zampieri A; Manry D; Ando Y; Miller S; Chan J; McLeod E; Cunningham KM; Wong LM; Xu H; Kamb A
iScience; 2024 Jun; 27(6):109913. PubMed ID: 38799557
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
Tokatlian T; Asuelime GE; Mock JY; DiAndreth B; Sharma S; Toledo Warshaviak D; Daris ME; Bolanos K; Luna BL; Naradikian MS; Deshmukh K; Hamburger AE; Kamb A
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091455
[TBL] [Abstract][Full Text] [Related]
3. A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo.
Sandberg ML; Wang X; Martin AD; Nampe DP; Gabrelow GB; Li CZ; McElvain ME; Lee WH; Shafaattalab S; Martire S; Fisher FA; Ando Y; Liu E; Ju D; Wong LM; Xu H; Kamb A
Sci Transl Med; 2022 Mar; 14(634):eabm0306. PubMed ID: 35235342
[TBL] [Abstract][Full Text] [Related]
4. HLA-A∗02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen.
Mock JY; Winters A; Riley TP; Bruno R; Naradikian MS; Sharma S; Jette CA; Elshimali R; Gahrs C; Toledo-Warshaviak D; West AP; Kamb A; Hamburger AE
Mol Ther Oncolytics; 2022 Dec; 27():157-166. PubMed ID: 36381658
[TBL] [Abstract][Full Text] [Related]
5. Robust
Manry D; Bolanos K; DiAndreth B; Mock JY; Kamb A
Front Immunol; 2022; 13():826747. PubMed ID: 35359952
[TBL] [Abstract][Full Text] [Related]
6. Geometric parameters that affect the behavior of logic-gated CAR T cells.
Partin AC; Bruno R; Shafaattalab S; Vander Mause E; Winters A; Daris M; Gahrs C; Jette CA; DiAndreth B; Sandberg ML; Hamburger AE; Kamb A; Riley TP
Front Immunol; 2024; 15():1304765. PubMed ID: 38343543
[TBL] [Abstract][Full Text] [Related]
7. A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy.
Wang X; Wong LM; McElvain ME; Martire S; Lee WH; Li CZ; Fisher FA; Maheshwari RL; Wu ML; Imun MC; Murad R; Toledo Warshaviak D; Yin J; Kamb A; Xu H
Toxicol Appl Pharmacol; 2022 Feb; 437():115894. PubMed ID: 35085592
[TBL] [Abstract][Full Text] [Related]
8. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
9. HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity.
Bassan D; Weinberger L; Yi J; Kim T; Weist MR; Adams GB; Foord O; Chaim N; Tabak S; Bujanover N; Lopesco Y; Vucci K; Schnair C; Levy-Knafo L; Kendall RL; Calzone FJ; Sharbi-Yunger A
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097342
[TBL] [Abstract][Full Text] [Related]
10. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
[TBL] [Abstract][Full Text] [Related]
11. Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins.
Wang X; Cabrera FG; Sharp KL; Spencer DM; Foster AE; Bayle JH
Mol Ther; 2021 Feb; 29(2):718-733. PubMed ID: 33554868
[TBL] [Abstract][Full Text] [Related]
12. Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor.
Fei F; Rong L; Jiang N; Wayne AS; Xie J
Mol Ther; 2022 Mar; 30(3):1215-1226. PubMed ID: 34801727
[TBL] [Abstract][Full Text] [Related]
13. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
[TBL] [Abstract][Full Text] [Related]
14. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.
Hoerster K; Uhrberg M; Wiek C; Horn PA; Hanenberg H; Heinrichs S
Front Immunol; 2020; 11():586168. PubMed ID: 33584651
[TBL] [Abstract][Full Text] [Related]
15. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
16. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
17. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L
Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295
[TBL] [Abstract][Full Text] [Related]
18. High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.
Degagné É; Donohoue PD; Roy S; Scherer J; Fowler TW; Davis RT; Reyes GA; Kwong G; Stanaway M; Larroca Vicena V; Mutha D; Guo R; Edwards L; Schilling B; Shaw M; Smith SC; Kohrs B; Kufeldt HJ; Churchward G; Ruan F; Nyer DB; McSweeney K; Irby MJ; Fuller CK; Banh L; Toh MS; Thompson M; Owen ALG; An Z; Gradia S; Skoble J; Bryan M; Garner E; Kanner SB
Cancer Immunol Res; 2024 Apr; 12(4):462-477. PubMed ID: 38345397
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection.
Li W; Zhu X; Xu Y; Chen J; Zhang H; Yang Z; Qi Y; Hong J; Li Y; Wang G; Shen J; Qian C
Front Immunol; 2022; 13():1052717. PubMed ID: 36532006
[TBL] [Abstract][Full Text] [Related]
20. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors.
Dragon AC; Beermann LM; Umland M; Bonifacius A; Malinconico C; Ruhl L; Kehler P; Gellert J; Weiß L; Mayer-Hain S; Zimmermann K; Riese S; Thol F; Beutel G; Maecker-Kolhoff B; Yamamoto F; Blasczyk R; Schambach A; Hust M; Hudecek M; Eiz-Vesper B
Front Immunol; 2023; 14():1219165. PubMed ID: 37915564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
